Physician profile
Eric C Weinman
NPI 1336180553
$2,251.58
in general payments reported to CMS, 2019-2025
15 companies · $907 in 2025
The $907 reported for 2025 was more than what 77% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $188 · 2021: $22.75 · 2022: $113 · 2023: $611 · 2024: $410 · 2025: $907.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,894 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,894.03 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $830.85 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $476.57 | 2020-2025 | Dupixent |
| Neurent Medical Limited | $241.34 | 2023-2025 | Neuromark Radiofrequency Console, Neuromark Device, Neuromark System |
| Optinose US, INC. | $221.20 | 2020-2025 | |
| Glaxosmithkline, LLC. | $186.16 | 2024-2025 | Nucala |
| Cochlear Americas | $82.73 | 2020 | |
| Stryker Corporation | $43.15 | 2020 | |
| Amgen INC. | $34.00 | 2025 | |
| Acclarent, INC | $33.08 | 2023 | Acclarent Balloon Inflation Device |
| Intersect Ent, INC. | $22.75 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $18.86 | 2025 | |
| Hikma Pharmaceuticals USA | $18.43 | 2024 | Ryaltris |
| Aerin Medical INC. | $16.59 | 2025 | |
| Inspire Medical Systems, INC. | $13.66 | 2023 | Inspire |
| Kaleo, INC. | $12.21 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Weinman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.